Navigation Links
Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension
Date:8/28/2013

Arena Pharmaceuticals GmbH.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the advancement, therapeutic indication, safety, efficacy and mechanism of action of APD811; the initiation of a Phase 2 clinical trial for APD811 and the further exploration of dosing regimens; the potential of APD811 and orally available, non-prostanoid IP agonists in general, including in improving patient care; the regulatory review and approval of BELVIQ; and Arena's focus, plans, goals, strategy, expectations, research and development programs, and ability to discover and develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: APD811 may not be sufficient for further development or regulatory review or approval; risks related to commercializing drugs, including regulatory, manufacturing and supply issues and the availability and use of BELVIQ; cash and revenues generated from BELVIQ, including the impact of competition; Arena's revenues will be based in part on estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding estimates or accounting policies may result in changes to Arena's guidance or previously reported results; the timing and outcome of regulatory review is uncertain, and BELVIQ may not be approved for marketing when expected or ever in combination with another drug, for another indication or using a different formulation or in any other territory for any indication; regulatory decisions in one territory may impact other regulatory decisions and Arena's business prospec
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2013 Financial Results
2. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, August 1
3. Arena Pharmaceuticals to Present at the 2013 Wells Fargo Securities Healthcare Conference
4. Former Semi-Pro Arena Football Player Bridged to Heart Transplant with the SynCardia Total Artificial Heart
5. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
6. BIOCOM Applauds Arena Pharmaceuticals Commitment to Innovation, Contributions to Southern California Life Science Community
7. Carena Launches 24/7 Virtual Care Delivery Service for Hospital Systems and Primary Care Clinics
8. Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
9. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, May 2
10. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
11. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Yesterday, former Congressman Patrick ... manufacturing facility. Rep. Kennedy and Dick Moberg ... cutting-edge research in neurological disease and treatment. ... advocate, Garen Staglin , created One Mind, ... changes that will radically accelerate the development and ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical ... today announced it has entered into an agreement with ... operates as EMD Serono in the United ... to collaborate with Merck KGaA,s biopharmaceutical division on the ... an undisclosed target using Ventana,s proprietary diagnostic assays. In ...
(Date:7/10/2014)... CVS Caremark Corporation (NYSE: CVS ) ... quarterly dividend of $0.275 (27.5 cents) per share on the ... 2014, to holders of record on July 21, 2014. ... dedicated to helping people on their path to better health ... United States . Through the company,s more than 7,600 ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... gout flares can be treated safely with Colcrys® (colchicine, ... often present physicians with treatment challenges, according to a ... Meeting of the American College of Rheumatology (ACR). ... conditions to consider, including cardiovascular and metabolic disorders, hypertension ...
... 8, 2010 Substandard and counterfeit versions of thirteen ... Ghana by the Medicines Quality Monitoring surveillance program. Set ... in collaboration with the U.S. Pharmacopeial Convention (USP) and ... samples antimalarials across the public and private sectors. It ...
Cached Medicine Technology:Data Presented at ACR Meeting Demonstrate Safety of Colcrys® (Colchicine, USP) for Treatment of Gout Flares in Patients with Multiple Co-Morbid Conditions 2Data Presented at ACR Meeting Demonstrate Safety of Colcrys® (Colchicine, USP) for Treatment of Gout Flares in Patients with Multiple Co-Morbid Conditions 3Data Presented at ACR Meeting Demonstrate Safety of Colcrys® (Colchicine, USP) for Treatment of Gout Flares in Patients with Multiple Co-Morbid Conditions 4Substandard and Counterfeit Antimalarial Drugs in Ghana Discovered by Cooperative Program of USP, Ghana Food and Drugs Board 2Substandard and Counterfeit Antimalarial Drugs in Ghana Discovered by Cooperative Program of USP, Ghana Food and Drugs Board 3
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July ... the hot flashes that often accompany menopause, new research suggests. ... percent of menopausal women, said Dr. Taraneh Shirazian, an assistant ... Icahn School of Medicine at Mount Sinai Hospital in New ... 10 hot flashes a day, and she added that hot ...
(Date:7/10/2014)... Dennis Thompson HealthDay Reporter ... of 10 adults make use of calorie information on menus, ... according to a new U.S. study. Women in particular ... Hee Lee-Kwan, an epidemiologist with the U.S. Centers for Disease ... they used menu labeling to help choose their meal, compared ...
(Date:7/10/2014)... experts on aggression, who research issues ranging from child ... World Meeting of the International Society for Research on ... , Georgia State University is hosting the prestigious world ... continents. , "We are excited to be bringing together ... will help produce fresh ideas about the causes, consequences ...
(Date:7/10/2014)... Childhood obesity is one of the top public health ... youths aged 2-19 classified as obese as of 2012. ... and organizations have taken to Twitter to discuss the ... Harris, PhD, assistant professor at the Brown School at ... the hashtag #childhoodobesity in tweets to track Twitter conversations ...
(Date:7/10/2014)... For those students looking to bump up their ... be spending more time in a library or study ... University research shows that students who were members of ... during their freshman and sophomore years had higher GPAs ... indicated that students with memberships stayed in school longer. ...
Breaking Medicine News(10 mins):Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 3Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3Health News:Study looks at how Twitter can be used to address specific health issues 2Health News:Want a higher GPA in college? Join a gym 2
... Barcelona, Spain: An experimental drug that attacks cancer in ... advanced melanoma, delaying progression of the disease and prolonging ... (Wednesday) at the European Cancer Conference (ECCO 14) in ... to chemotherapy more than doubled the amount of time ...
... 26 Biomedtex Inc.,(Pink Sheets: PDNL.PK) ("Biomed" or ... that A. Marc Rocca, 42, will be,President and ... mission is to identify, evaluate and assess a ... and then,seek to capture and promote innovations with ...
... Nycomed Acquires Exclusive Rights Outside North America in Deal Valued ... ... N.J. and ZURICH, Switzerland, Sept. 26, NPS Pharmaceuticals, Inc. (Nasdaq: ... into a definitive agreement,which licenses to Nycomed the rights to ...
... research has yielded a clearer picture of which biomarkers ... colon cancer, bringing closer the day when patients who ... those that will, get the more aggressive treatment they ... doctors plan treatment of colon cancer chiefly by staging ...
... work investigating the reproducibility of glycemic index values, ... Research Center on Aging at Tufts University (USDA ... determinations (measure of the rate of glucose absorption ... white bread, resulted in a relatively high level ...
... to Home and the ... ... pioneer and largest provider of retail-,based health care in the United ... stores in Southeastern,Pennsylvania and Southern New Jersey. MinuteClinic plans to open ...
Cached Medicine News:Health News:New type of drug shows promise in attacking melanoma in an innovative way 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 3Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 4Health News:Study makes progress in zoning in on biomarkers for better colon cancer treatment 2Health News:Glycemic index values are variable, report researchers 2Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Philadelphia Metro Area 2Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Philadelphia Metro Area 3Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Philadelphia Metro Area 4Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Philadelphia Metro Area 5
The S7 Elite is the premium device in ResMeds award-winning S7 series. All S7 devices include an option of integrated humidification....
... Enjoy freedom and flexibility with ... optional rechargeable battery pack, the system ... household current. Also includes an integrated ... provides enough water for one nights ...
The clarity and performance of glass with shatterproof safety of plastic....
Hemato-clad Hematocrit Tubes combine the precision of glass with the safety provided by a Mylar® overwrap. Now you can give your laboratory staff safety with no compromise in accuracy....
Medicine Products: